Recent Updates
Recently added Catalysts

Commercial naproxen

Phase 3

Post-operative Dental Pain | Small molecule | Pain |Johnson & Johnson|Last Updated: Apr 9, 2020

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment501
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03566979Efficacy and Safety Study of a Test Naproxen Sodium 220mg Tablet in Postoperative Dental PainPHASE3 COMPLETED 501Aug 13, 2018Apr 15, 2019Apr 9, 20201 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Time to Confirmed Perceptible Pain Relief
12 hours

Minutes until confirmed first perceptible pain relief was achieved. Stopwatch is started after the participant takes the study medication. The participant is instructed to stop the stopwatch when they first begin to feel any pain relief. The first perceptible pain relief is confirmed if the participant also stopped the second stopwatch indicating meaningful pain relief.

Secondary Endpoints
Percentage of Participants With Confirmed Perceptible Pain Relief From 45 Minutes to Successively Earlier Minutes in One-minute Increments
Up to 45 minutes after dosing
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Test naproxen sodium tabletEXPERIMENTALSingle dose of 440 mg of naproxen sodium administered as two Test Naproxen Sodium 220 mg tablets (Test NPX)
Commercial naproxen sodium tabletACTIVE_COMPARATORSingle dose of 440 mg of naproxen sodium administered as two commercial naproxen sodium 220 mg tablets
Commercial naproxen sodium liquid gels capsuleACTIVE_COMPARATORSingle dose of 440 mg of naproxen sodium administered as two 220 mg commercial liquid gels capsules
Placebo tabletPLACEBO_COMPARATORSingle dose of two Placebo tablets
Interventions
NameTypeDescription
Test naproxen sodium tabletDRUGSingle dose of 2 test naproxen sodium 220 mg tablets
Commercial naproxen sodium tabletDRUGSingle dose of 2 naproxen sodium 220 mg tablets
Commercial naproxen sodium liquid gels capsuleDRUGSingle dose of 2 naproxen sodium 220 mg liquid gel capsules
Placebo tabletDRUG2 placebo tablets
Unlock Study Design Details
Eligibility Criteria
Age Range17 Years — 50 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: 1. 17 - 50 years old 2. Weigh 100 pounds or greater and have a body mass index (BMI) of 17.5 to 30.4 (inclusive) at screening 3. Dental extraction of three or four third molars 4. Meets post-surgical pain 5. Females of childbearing potential and males agree to contraceptive requ...

Countries:United States
Unlock Eligibility Criteria